Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion

Lasse Jørgensen Cehofski*, Anders Kruse, Mads Odgaard Mæng, Benedict Kjaergaard, Jakob Grauslund, Bent Honoré, Henrik Vorum*


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

16 Downloads (Pure)


Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pigs, experimental CRVO was induced in both eyes with argon laser. The right eyes received an intravitreal injection of 0.05 mL bevacizumab (n = 9), while the left control eyes received 0.05 mL saline water (NaCl). Retinal samples were collected 15 days after induced CRVO. Label-free quantification nano-liquid chromatography-tandem mass spectrometry identified 59 proteins that were regulated following bevacizumab treatment. Following bevacizumab intervention, altered levels of bevacizumab components, including the Ig gamma-1 chain C region and the Ig kappa chain C region, were observed. Changes in other significantly regulated proteins ranged between 0.58-1.73, including for the NADH-ubiquinone oxidoreductase chain (fold change = 1.73), protein-transport protein Sec24B (fold change = 1.71), glycerol kinase (fold change = 1.61), guanine-nucleotide-binding protein G(T) subunit-gamma-T1 (fold change = 0.67), and prefoldin subunit 6 (fold change = 0.58). A high retinal concentration of bevacizumab was achieved within 15 days. Changes in the additional proteins were limited, suggesting a narrow mechanism of action.

TidsskriftJournal of Personalized Medicine
Udgave nummer11
StatusUdgivet - 7 nov. 2023


Dyk ned i forskningsemnerne om 'Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion'. Sammen danner de et unikt fingeraftryk.